Product Labels Miss Hidden Chemicals - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Product Labels Miss Hidden Chemicals

Testing found that nearly 60% of top-rated "Go" products failed contamination testing.

  • By

  • Teraya Smith

  • August 12, 2026

  • 2 min

Share

Objective:

To identify unlabeled potentially harmful chemicals in personal care and cleaning products marketed as 'natural,' 'non-toxic,' and 'fragrance-free.'

Approach:
  • Chemical Testing Methodology: Nontargeted chemical testing was conducted using high-resolution two-dimensional gas chromatography time-of-flight mass spectrometry with machine learning–assisted identification.
Key Findings:
  • 98% of the 113 products tested contained at least 1 unlabeled potentially harmful chemical.
  • 85% contained at least 1 unlabeled chemical with known or suspected health hazards.
  • 58% of products failed contamination criteria.
  • An average of 51 detected chemicals were found per product, compared to 16 ingredients listed on labels.
  • 26% of products contained chemicals contradicting label claims, including products advertised as free of phthalates, parabens, fragrance, silicone, or oxybenzone.
Interpretation:

Label-based classifications did not reliably distinguish products that failed contamination testing.

Limitations:
  • The analysis evaluated chemical hazard rather than clinical risk.
  • It could not definitively establish the sources of individual contaminants.
  • The study did not account for exposure dose, route, or bioavailability.
  • Products were not selected to represent the broader market.
Conclusion:

COVID-19–related supply-chain disruptions may have influenced product composition.

Sources:

Original Source(s)

Product Labels Miss Hidden Chemicals

  • by Teraya Smith

  • August 12, 2026

Related Content

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

Inside the hip osteoarthritis microbiome

Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.